Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effect of Beginning Recombinant Erythropoietin Treatment Within the First Week of Life, Among Very-Low-Birth-Weight Neonates, on “Early” and “Late” Erythrocyte Transfusions: A Meta-Analysis

Journal of Perinatology volume 24, pages 24–29 (2004)Cite this article

Abstract

OBJECTIVES: Erythrocyte transfusions to neonates can be categorized as “early” if given during the first 3 weeks of life and “late” if given thereafter. We used a meta-analysis to determine whether recombinant erythropoietin (rEpo) administration to very-low-birth-weight (VLBW, <1500 g) neonates, beginning in the first week of life, reduces either “early” or “late” transfusions.

STUDY DESIGN AND METHODS: Studies that used a randomized, placebo-controlled, double-masked design were deemed acceptable. We identified 12 acceptable, relevant, clinical trials. Additional data not provided in the publications were obtained from two of the authors.

RESULTS: The acceptable studies involved an aggregate of 561 rEpo and 529 placebo recipients. If rEpo was begun in the first week of life, the summary odds ratio (OR) for receiving any transfusion (“early” or “late”) was 0.52, 95% confidence interval (CI): 0.34 to 0.79 (p=0.001). The OR for receiving an “early” transfusion was 0.54 (95% CI: 0.25 to 1.15; p=0.055), and the OR for receiving a “late” transfusion was 0.56 (95% CI: 0.37 to 0.83; p=0.036). Heterogeneity among studies was too great to estimate the effect of rEpo on the number of transfusions received or the volume of blood transfused (p<0.001 for the Q-test statistic). Subgroup analysis suggested that when rEpo is begun in the first week of life, neonates 1000 to 1500 g and >29 weeks are more likely to completely avoid transfusion than are extremely low-birth-weight (ELBW, <1000 g) neonates. No dose–response relationship was apparent between rEpo dose or iron dose and transfusion. No difference was apparent depending on whether the rEpo was given subcutaneously vs intravenously.

CONCLUSION: If rEpo is begun in the first week of life, a moderate reduction can be expected (p=0.001) in the proportion of VLBW neonates transfused. Reduction is less significant in “early” transfusion (p=0.055) than in “late” transfusion (p=0.036). Such treatment is not likely to eliminate transfusions among ELBW neonates completely.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Vamvakas EC, Strauss RG . Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion 2001;41:406–415.

    Article  CAS  Google Scholar 

  2. Juul SE . Erythropoietin in the neonate. Curr Prob Pediatr 1999;29:133–149.

    Article  Google Scholar 

  3. Strauss RG . Blood banking and transfusion issues in perinatal medicine. In: Christensen RD, editor. Hematologic Problems of the Neonate. Philadelphia, PA: WB Saunders Co.; 2000. p. 405–426.

    Google Scholar 

  4. Zipursky A . Erythropoietin therapy for premature infants: cost without benefit? Pediatr Res 2000;48:136.

    Article  CAS  Google Scholar 

  5. Mulrow CD, Oxman AD, editors. Cochrane. Collaborative Handbook [updated 21 Oct 1996]. Available in the Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration; issue 3. Oxford Updated software; Updated quarterly. Available from: BMJ Publishing Group, London 1996.

  6. Emmerson A, Coles H, Stern C, Pearson T . Double-blind trial of recombinant human erythropoietin in preterm infants. Arch Dis Child 1993;68:291–296.

    Article  CAS  Google Scholar 

  7. Soubasi V, Kremenopoulos G, Diamandi E, Tsantali C, Tsakiris D . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatr Res 1993;34:675–679.

    Article  CAS  Google Scholar 

  8. Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D . Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. J Pediatr 1995;127:291–297.

    Article  CAS  Google Scholar 

  9. Ohls R, Osborne K, Christensen R . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J Pediatr 1995;126:421–426.

    Article  CAS  Google Scholar 

  10. Lauterbach R, Kachlik P, Pawlik D, Bajorek I . Recombinant human erythropoietin in the treatment of anemia of prematurity. Pediatr Pols 1995;9:739–744.

    Google Scholar 

  11. Ohls R, Harcum J, Schibler K, Christensen R . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr 1997;131:661–665.

    Article  CAS  Google Scholar 

  12. Lima-Roger V, Torres-Montes A, Espinosa S, et al. Efficacy of treating very low birth weight and critical ill neonates with erythropoietin in the first 72 h of age: a randomized, placebo-controlled trial. Sangre 1998;43:191–195.

    Google Scholar 

  13. Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Pediatr 2000;105:1066–1072.

    Article  CAS  Google Scholar 

  14. Ohls R, Ehrenkranz R, Wright L, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: A multicenter, randomized, controlled trial. Pediatrics 2001;108:934–942.

    Article  CAS  Google Scholar 

  15. Obladen M, Maier R, Grauel E, et al. Efficacy and Safety of recombinant human erythropoietin to prevent anemia of prematurity. Contrib Nephrol 1991;8:314–326.

    Article  Google Scholar 

  16. Maier R, Obladen M, Scigalla P, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med 1994;330:1173–1178.

    Article  CAS  Google Scholar 

  17. Maier R, Obladen M, Muller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 2002;141:8–15.

    Article  CAS  Google Scholar 

  18. De la Torre M, Gascon F, Zapatero M, Guzman J, Huertas D, Ruiz D Jaraba P . Prophylaxis of anemia of prematurity with erythropoietin. Case control study. An Esp Pediatr 2000;53:243–248.

    Article  Google Scholar 

  19. Trenseteaux A, Egreteau L, Santerne B, Morville P . Recombinant human erythropoietin in preterm infants: evaluation of one year of experience. Arch Pediatr 1999;6:944–951.

    Article  Google Scholar 

  20. Hays S, Guy B, Boulard M, et al. Transfusion malgréerythropoïetine recombinante: échec ou limite du traitement? Etude d'une cohorte annuelle de poids de naissance inférieur a 1500 g. Arch Pediatr 2001;8:355–360.

    Article  CAS  Google Scholar 

  21. Klosowski S, Djebara A, Bachiri A, Haouari N, Thelliez P, Morisot C . Anémie du prématuré et traitement par erythropoïetine humaine recombinante (rHuEPO): Quel bénéfice? Arch Pediatr 2001;8:1399–1400.

    Article  Google Scholar 

  22. Atasay B, Gunlemez A, Akar N, Arsan S . Does early erythropoietin therapy decrease transfusions in anemia of prematurity? Indian J Pediatr 2002;69:389–391.

    Article  Google Scholar 

  23. Carnielli V, Montini G, Da Riol R, Dall' Amico R, Cantarutti F . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Pediatr 1992;121:98–102.

    Article  CAS  Google Scholar 

  24. Yeo C, Choo S, Ho L . Effect of recombinant human erythropoietin on transfusion needs in preterm infants. J Paediatr Child Health 2001;37:352–358.

    Article  CAS  Google Scholar 

  25. Maier R, Obladen M, Kattner E, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. J Pediatr 1998;132:866–870.

    Article  CAS  Google Scholar 

  26. Brown M, Keith III J . Comparison between two and five doses a week of recombinant human erythropoietin of anemia of prematurity: a randomized trial. Pediatrics 1999;104:210–215.

    Article  CAS  Google Scholar 

  27. Serra M, Espallargues M . Metaanálisis de ensayos clínicos. Pharm Care Esp 2000;2:83–92.

    Google Scholar 

  28. Petitti D . Meta-Analysis, decision analysis, cost-effectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. New York Oxford: Oxford University Press; 2000: 75–118.

  29. Meyer MP, Meyer JH, Commeford A, et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double blind, placebo-controlled study. Pediatrics 1994;93:918–923.

    CAS  PubMed  Google Scholar 

  30. Lee DA, Slagel TA, Jackson TM, Evans CS . Reducing blood donor exposure in low birth weight infants by the use of older, unwashed packed red blood cells. J Pediatr 1995;126:280–286.

    Article  CAS  Google Scholar 

  31. Strauss RG, Burmeister LF, Johnson K, Cress G, Cordle D . Feasibility and safety of AS-3 red blood cells for neonatal transfusions. J Pediatr 2000;136:215–219.

    Article  CAS  Google Scholar 

  32. Ohls RK . The use of erythropoietin in neonates. Clin Perinatol 2000;27:681–696.

    Article  CAS  Google Scholar 

  33. Bifano EM, Curran TR . Minimizing donor bloods exposure in the neonatal intensive care unit. Current trends and future prospects. Clin Perinatol 1995;22:657–669.

    Article  CAS  Google Scholar 

  34. Lin JC, Strauss RG, Kulhavy JC, et al. Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics 2000;106:E19.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. R.D.C. was supported by Grants HL-61798, HL-69990, and HD-42308 (R.D.C.), D.A.C. supported by HD-01180 and HD-42326 from the National Institutes of Health.

Authors and Affiliations

  1. Division of Neonatology, Department of Pediatrics, University of South Florida College of Medicine and All Children's Hospital, St. Petersburg, FL, USA

    Anne C Kotto-Kome MD, Darlene A Calhoun DO & Robert D Christensen MD

  2. National Institute of Perinatology, Mexico City, Mexico

    Maria G Garcia MD

Authors
  1. Anne C Kotto-Kome MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria G Garcia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darlene A Calhoun DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert D Christensen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kotto-Kome, A., Garcia, M., Calhoun, D. et al. Effect of Beginning Recombinant Erythropoietin Treatment Within the First Week of Life, Among Very-Low-Birth-Weight Neonates, on “Early” and “Late” Erythrocyte Transfusions: A Meta-Analysis. J Perinatol 24, 24–29 (2004). https://doi.org/10.1038/sj.jp.7211018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211018

This article is cited by

Search

Advanced search

Quick links